New anticancer drugs are fast entering the clinical arena, promising patients with previously resistant tumors more effective therapies that will allow them to live longer. However, adverse renal effects can occur in treated individuals with underlying risk factors, necessitating a familiarity with nephrotoxic effects among the nephrology community. Acute kidney injury, variable levels of proteinuria, hypertension, electrolyte abnormalities, and chronic kidney disease are the most prevalent clinical nephrotoxic symptoms of these medicines. Thus, nephrologists will benefit from an update on older medications with newly known nephrotoxic potential as well as newer substances that may be associated with kidney injury in order to practice successfully in the 'onco-nephrology' arena. With that in mind, the purpose of this brief update is to present doctors with the most up-to-date information on the nephrotoxicity of a class of anticancer drugs.
